These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 20957139)

  • 21. Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.
    Kim KH; Jelovac D; Armstrong DK; Schwartz B; Weil SC; Schweizer C; Alvarez RD
    Gynecol Oncol; 2016 Feb; 140(2):210-4. PubMed ID: 26644263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
    Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
    Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
    Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
    Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic and toxicity considerations for the use of anthracyclines in ovarian cancer treatment.
    Morotti M; Valenzano Menada M; Venturini PL; Ferrero S
    Expert Opin Drug Metab Toxicol; 2011 Jun; 7(6):707-20. PubMed ID: 21434836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
    J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
    Naumann RW; Coleman RL; Burger RA; Sausville EA; Kutarska E; Ghamande SA; Gabrail NY; Depasquale SE; Nowara E; Gilbert L; Gersh RH; Teneriello MG; Harb WA; Konstantinopoulos PA; Penson RT; Symanowski JT; Lovejoy CD; Leamon CP; Morgenstern DE; Messmann RA
    J Clin Oncol; 2013 Dec; 31(35):4400-6. PubMed ID: 24127448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epithelial ovarian cancer: role of pegylated liposomal Doxorubicin in prolonging the platinum-free interval and cancer antigen 125 trends during treatment.
    Tanguay JS; Ansari J; Buckley L; Fernando I
    Int J Gynecol Cancer; 2009 Apr; 19(3):361-6. PubMed ID: 19407560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain.
    Ojeda B; de Sande LM; Casado A; Merino P; Casado MA
    Br J Cancer; 2003 Sep; 89(6):1002-7. PubMed ID: 12966416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
    Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
    Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
    Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
    Parma G; Mancari R; Del Conte G; Scambia G; Gadducci A; Hess D; Katsaros D; Sessa C; Rinaldi A; Bertoni F; Vitali A; Catapano CV; Marsoni S; van de Velde H; Colombo N
    Int J Gynecol Cancer; 2012 Jun; 22(5):792-800. PubMed ID: 22635029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of anthracyclines in second-line therapy of ovarian cancer.
    Vermorken JB
    Int J Gynecol Cancer; 2003; 13 Suppl 2():178-84. PubMed ID: 14656277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.
    Robert NJ; Vogel CL; Henderson IC; Sparano JA; Moore MR; Silverman P; Overmoyer BA; Shapiro CL; Park JW; Colbern GT; Winer EP; Gabizon AA
    Semin Oncol; 2004 Dec; 31(6 Suppl 13):106-46. PubMed ID: 15717740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer.
    Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
    Data Brief; 2020 Jun; 30():105465. PubMed ID: 32346557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors.
    Villanucci A; Tavella K; Vannini L; Rossi V; Nobili S; Amunni G; Mazzei T; Mini E
    Mol Clin Oncol; 2018 Dec; 9(6):635-639. PubMed ID: 30546893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer.
    Erriquez J; Becco P; Olivero M; Ponzone R; Maggiorotto F; Ferrero A; Scalzo MS; Canuto EM; Sapino A; Verdun di Cantogno L; Bruna P; Aglietta M; Di Renzo MF; Valabrega G
    Gynecol Oncol; 2015 Sep; 138(3):627-33. PubMed ID: 26100858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
    Hong RL; Tseng YL
    Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma.
    Sharpe M; Easthope SE; Keating GM; Lamb HM
    Drugs; 2002; 62(14):2089-126. PubMed ID: 12269857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-minimization analysis of pegylated liposomal doxorubicin versus topotecan for the treatment of ovarian cancer in Italy.
    Capri S; Cattaneo G
    Clin Ther; 2003 Jun; 25(6):1826-45. PubMed ID: 12860501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.